Enhancing the Extraordinary

Our Story
 

Enhancing the Extraordinary

Our Story
Rick Klausner, M.D.,Founder & Board Chair

Founder's Vision

Lyell Founder and Board Chair Rick Klausner, M.D., shares his vision for conquering oncology’s unfinished business.

Our Science icon

Our Science

Technology designed to generate CAR T cells that deliver more durable outcomes for patients with cancer.

Our Pipeline icon

Our Pipeline

Our pipeline targets solid tumors and hematologic malignancies with significant unmet medical need.

Dedicated to Patients

An unwavering focus on science guides our mission to deliver transformative CAR T-cell therapies for patients with solid tumors and hematologic malignancies.

Learn More
Latest News

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, today announced that an abstract highlighting

View All News

Join Our Team

At Lyell, we are driven by our mission and focused on developing transformative therapies to improve the lives of patients.

Join our team of ambitious Lyellites who are committed to defeating cancer through innovation.

See Open Positions